Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Aevis Bio, Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 distinct art units, meaning each action has its own examiner and examination-group context. Counsel should coordinate scientific terminology across the portfolio while keeping the factual and claim analysis specific to each biotechnology or pharmaceutical record.
COUGHLIN, MATTHEW P is the busiest examiner, with 1 pending matter. No examiner has more than one current assignment in the reported docket. A distributed prosecution workflow is therefore appropriate, with separate responses supported by a common review of biological concepts and claim definitions where the applications overlap.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681029 | IMMUNOREGULATORY AMIDE DERIVATIVE WITH IMPROVED MATERIAL PROPERTIES | SHIAO, YIH-HORNG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840873 | NOVEL POMALIDOMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | COUGHLIN, MATTHEW P | — |
| 18681029 | IMMUNOREGULATORY AMIDE DERIVATIVE WITH IMPROVED MATERIAL PROPERTIES | SHIAO, YIH-HORNG | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1699 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840873 | NOVEL POMALIDOMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | COUGHLIN, MATTHEW P | 1626 | §112DP | Final Rejection | — | Pending | Aug 29, 2024 |
| 18841330 | USE OF NOVEL POMALIDOMIDE DERIVATIVE FOR TREATING BRAIN DISEASES | OTTON, ALICIA L | 1699 | §112DP | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18681029 | IMMUNOREGULATORY AMIDE DERIVATIVE WITH IMPROVED MATERIAL PROPERTIES | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAevis Bio, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Matthew P Coughlin has the most, with 1 of Aevis Bio, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
